LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Home・Akciju saraksts・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Slēgts

4.03 2.54

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

Max

4.07

Galvenie mērījumi
By Trading Economics
Ienākumi	466K -27M
Pārdošana	2M 15M
Peļņas marža	-178.834
Darbinieki	141
EBITDA	-2M -29M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+273.83% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 11. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	5.9M 234M
Iepriekšējā atvēršanas cena	1.49
Iepriekšējā slēgšanas cena	4.03

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

3.17 / 3.4644 Atbalsts un pretestība

Voyager Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 8. maijs 23:55 UTC

Peļņas

Review & Preview: Still Going Strong -- Barrons.com

2026. g. 8. maijs 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 8. maijs 20:49 UTC

Peļņas

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

2026. g. 8. maijs 20:25 UTC

Peļņas

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

2026. g. 8. maijs 19:43 UTC

Peļņas

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

2026. g. 8. maijs 19:43 UTC

Peļņas

Cencosud 1Q Net $115M

2026. g. 8. maijs 19:20 UTC

Tirgus saruna

Oil Futures End Session Higher, But Down on the Week -- Market Talk

2026. g. 8. maijs 19:18 UTC

Peļņas

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

2026. g. 8. maijs 19:16 UTC

Peļņas

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

2026. g. 8. maijs 19:08 UTC

Peļņas

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

2026. g. 8. maijs 19:05 UTC

Peļņas

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

2026. g. 8. maijs 19:02 UTC

Tirgus saruna

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

2026. g. 8. maijs 18:51 UTC

Peļņas

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

2026. g. 8. maijs 18:49 UTC

Peļņas

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

2026. g. 8. maijs 18:41 UTC

Peļņas

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

2026. g. 8. maijs 17:38 UTC

Tirgus saruna

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

2026. g. 8. maijs 17:14 UTC

Peļņas

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

2026. g. 8. maijs 17:04 UTC

Tirgus saruna

Zcash Caps Off Parabolic Week -- Market Talk

2026. g. 8. maijs 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 8. maijs 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 8. maijs 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 8. maijs 15:39 UTC

Tirgus saruna

Gold Seen Transitioning Away From 'Corrective Phase' -- Market Talk

2026. g. 8. maijs 15:39 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 8. maijs 15:39 UTC

Tirgus saruna

Canada's Job Market Sees Worst Start in Years -- Market Talk

2026. g. 8. maijs 15:36 UTC

Tirgus saruna

A Jump in Canada's Jobless Rate May Turn Out to Be a Blip -- Market Talk

2026. g. 8. maijs 15:20 UTC

Tirgus saruna

'Altcoin Season' Indicator on the Rise -- Market Talk

2026. g. 8. maijs 15:20 UTC

Tirgus saruna

Peļņas

Enbridge Gas Pipelines, Distribution Units Drive 1Q Beat -- Market Talk

2026. g. 8. maijs 15:05 UTC

Tirgus saruna

Bitcoin Slips Back Below the $80k Mark -- Market Talk

2026. g. 8. maijs 14:42 UTC

Tirgus saruna

Tough Times for Canadian Teenagers Looking for Work -- Market Talk

2026. g. 8. maijs 14:39 UTC

Tirgus saruna

Canadian Labor Market Suggests Persistent Higher Inflation Unlikely -- Market Talk

Salīdzinājums

Cenas izmaiņa

Voyager Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

273.83% augšup

Prognoze 12 mēnešiem

Vidējais 15.14 USD 273.83%

Augstākais 25 USD

Zemākais 8 USD

Pamatojoties uz 9 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

9 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 9 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

3.17 / 3.4644Atbalsts un pretestība

Recent bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.